Kolkata, October 8, 2026 : In
a decisive move aligned with the Ministry of AYUSH's ambitious target of
achieving USD 213 billion by 2030 for the sector, legacy homoeopathy major
Powell Group has announced a renewed and aggressive push to bolster its
Pan-India and export sales for its Homoeopathy Division.
Prof. Dr. Soumik Banerjee, MSc, PhD, Chief Scientific Officer of the
company, said Powell is reorganising with renewed vigour to significantly
contribute to this National Mission. "We are inspired by the Government's
vision and want to be a meaningful contributor to it," he said.
The strategy is being driven under the leadership and guidance of MD
& CEO Dr. Sudipta Narayan Roy. The company is now leveraging evidence-based
AYUSH medicines and sharply increasing investments in clinical validations of
its products. His vision, Prof. Banerjee said, is to align the company with the
national ambition and mainstreaming of AYUSH through scientific validation.
Carrying forward a rich legacy, Powell was founded by Late Prof. Dr.
Sailendra Nath Roy, a visionary in the AYUSH healthcare sector. The same
ideology and philosophy are being carried forward with commitment by Co-founder
and Chairperson of the Group, Dr. Rita Roy, who continues to anchor the
organisation in its core values of trust, science and service.
What makes Powell a distinctive and investable model for stakeholders
is its unparalleled repertoire of almost 30,000 generic SKUs, a manufacturing
depth few in the sector can match. To fuel its next phase of growth into
diverse verticals, the company has also tied up with Dubai-based financial
consultancy firm SR LLC-FZ for the exploration of FDI and global partnerships.
Prof. Banerjee added that the immediate focus is on aggressive scaling
in the Homoeopathy market. In line with this, the company has appointed Mr.
Shovan Chaule as SBU Head of the Homoeopathy Division. A Gold Medalist in
Pharmaceutical Technology and a management graduate from Delhi University, Mr.
Chaule started his career at Lupin, later held key managerial positions at Abbott
and other leading brands, and for over a decade served in senior management
roles in Homoeopathy companies, including WSI, a German Homoeopathy MNC. His
experience and expertise will be deployed for aggressive market expansion of
the division.
Adding to the growth narrative, Dr. Subrata Chatterjee, MD, PhD,
presently Medical Director of the company and Former Executive Director &
CEO of Allen Labs, said the company is prudently exploring high-potential
verticals like OTC & FMCG with Ayurvedic products, anticipating a
substantial market share in the burgeoning AYUSH segment.
With scientific leadership, a legacy of five decades, a massive
product portfolio and fresh leadership infusion, Powell is positioning itself
not just as a participant but as a frontrunner in India's AYUSH growth story -
a promising proposition for investors and stakeholders alike.